The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated -1A frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
(HTS) data. The classic use of NGSEP is a reference guided construction and downstream analysis of large datasets of genomic variation. NGSEP performs accurate detection and genotyping of Single Nucleotide Variants (SNVs), small and large indels, short tandem repeats (STRs), inversions, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "1A" frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "1A" frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated -1A frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "-1A" frameshift mutation in human TGFRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "1A" frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "-1A" frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "-1A" frameshift mutation in human TGFRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and ...
The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associated "−1A" frameshift mutation in human TGFβRII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said peptide is presented by a Class I MHC, and...